NYSE CONTENT ADVISORY: PRE-MARKET UPDATE + RARE DISEASE DAY AWARENESS
NEW YORK, Feb. 28, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Dr. Kinnari Patel, President, Head of R&D + COO at Rocket Pharma joins Trinity Chavez to discuss the impact of rare disease. Listen to the full...
A*STAR And MojiaBio To Develop Next-gen Sustainable Biomanufacturing Platform In Singapore
SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- This initiative aims to produce eco-friendly bio-based molecules from low-cost, eco-friendly sources. Key benefits include: Cost-parity with conventional methods: Unlike existing bio-based molecules production, this initiative aims to achieve cost-parity with conventional processes by utilising low-cost renewable sources like methanol. Wide-ranging industry applications: The sustainable bio-based...
Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class Immunotherapy for Solid Tumors
DONGGUAN, China, Feb. 28, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for FP008, its first-in-class immunocytokine designed to address the unmet need in patients with...
Lime AI Debuts at MWC 2025: A Game-Changer in Stress Management
SEOUL, South Korea, Feb. 28, 2025 /PRNewswire/ -- BlueSignum, the innovator behind DailyBean, is set to launch its latest breakthrough in mental wellness at MWC 2025. Lime AI is designed to provide personalized insights and guidance in stressful situations anytime, anywhere. Backed by professional psychological research and cutting-edge AI technology, Lime AI is here to redefine how we manage...
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor calls to discuss recent developments on its mRNA therapeutic vaccine programs. The English session of the conference call will be held at 9:00 pm...
KBP to Contest Injunction Obtained by Novo Nordisk
SINGAPORE, Feb. 28, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a recent decision by the Singapore International Commercial Court ("SICC"), which granted an injunction sought by Novo Nordisk A/S ("Novo Nordisk") against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang") on February 14, 2025. The SICC decision was issued on...
CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease
SHANGHAI, Feb. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR-T therapy targeting CD19/CD20, has administered at the starting dose specified in the clinical protocol to the...
EPILEPSY COMMUNITY CALLS FOR MORE SUPPORT FOR THE UNSUNG HEROES OF EPILEPSY
While Australian researchers are paving the way in epilepsy care, findings show the significant burden on carers and parents with children living with severe epilepsies. SYDNEY, Feb. 28, 2025 /PRNewswire/ -- Australian findings into patients with developmental and epileptic encephalopathies (DEEs), the most severe group of epilepsies, highlight the significant burden and responsibility of the condition on parents and carers of...
Ubie and Nucleus Genomics Partner to Enhance Access to Genetic Testing and Drive Early Screening for Improved Health Outcomes
Genetic testing can be critical to ensuring the early diagnosis and proper treatment of serious disease for patients of all ages The partnership combines Ubie's AI-driven symptom identification and high rates of patient engagement with Nucleus Genomics' cutting-edge complete DNA sequencing Engaging with patients while they are looking for...
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
PROVIDENCE, R.I., Feb. 27, 2025 /PRNewswire/ -- EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax's immunoinformatics team in 2014 and spearheaded the development of a new computational platform for developing personalized, neoantigen-based cancer vaccines: Ancer®. He subsequently oversaw translational work of this...
